Skip to content
Products
Close Products
Open Products
TUBEs
Pan-Selective TUBEs
K48 TUBEs
K63 TUBEs
Linear-M1 TUBEs
TUBEs for Detection
Magnetic TUBEs
Custom Manufacturing
PROTAC & Molecular Glue Tools
PROTAC Ubiquitination Assays
PROTAC Ubiquitin Plates
In Vitro Assay in PROTAC
Ubiquitin Ligases and Enzymes
E1 Ubiquitin Activating Enzymes
E2 Ubiquitin Conjugating Enzymes
E3 Ubiquitin Ligases
Proteasomal Research Tools
Deubiquitinating Enzymes (DUBS)
USP Family of DUBs
UCH Family of DUBs
OTU Family of DUBs
JAMM Family of DUBs
MJD Family of DUBs
Viral and Bacterial DUBs
Deneddylases
DeSUMOylases
DUB Screening Assays
Antibodies
Kits and Plates
Colormetric Assays
E1-E2-E3 Assays
High-Throughput Plates
Target Protein Ubiquitination
Ubiquitination Assay
SUMO Protein Expression System
Bacteria
Mammalian Cells
Insect Cells
Yeast
Ubiquitin Chains and Derivatives
K to R Mutants
Ubiquitin Derivatives
Sumo Derivatives Chain
Isotropically-Labeled Ubiquitin
Small Molecule Modulators
Autophagy
E1-E2-E3 Inhibitors
DUB Inhibitors
Proteasome Inhibitors
P97 Inhibitors
Neurodegeneration Diagnostics and Research Tools
Phospho-Ubiquitin Antibodies
Phospho-Ubiquitin Chains and Derivatives
PINK1 and Parkin Pathway Proteins
Neuronal DUBs and Ligases
Phospho-Polyubiquitinated Enriched Lysates
TUBEs
Our Technologies
Close Our Technologies
Open Our Technologies
Tandem Ubiquitin Binding Entities (TUBEs)
E3 Ligase Assays
PROTAC Discovery Platform
Molecular Glue Discovery Platform
Mass Spec Proteomics
Imaging
Pulldown
Luciferase Reporters Applications for TPD
Reporters
PROTAC Applications
Molecular Glue Applications
Molecular Glue Degraders
Targeting E3 Ligase Applications
Substrate Targeting Applications
Ligase and Substrate Screening
PROTAC and DUBTAC Drug Discovery
LYTACs
BioPROTACs - MRNA Chimeras
Antibody Mediated Degradation
Exracellular Targeted Protein Degradation
Ubiquitin and Ubiquitin Chains
Ubiquitin Chains for DUB Screening
Biotinylated Ubiquitin Chains
Ubiquitin K to R mutants
SUMO Technology & Protein Expression
Polypeptide Manufacturing
Therapeutic Proteins, Dramatic Enhancement
Nanobodies and Single Chain Antibodies
Vaccine Manufacturing with SUMO
Gene Therapy: SUMO to the rescue
Neurodegeneration
Dysfunction of the Ubiquitin Proteasome System
Phospho-Ubiquitin as a Biomarker
Parkinsons Disease
Alzheimer’s Disease
R&D Services
Close R&D Services
Open R&D Services
PROTAC & Molecular Glues
PROTAC Degradation Assays
PROTAC Ubiquitination Assays
Target Exploration and Validation
Novel E3 Ligases For PROTAC
PROTAC Ternary Complex Formation Assays
PROTAC for Cancer
PROTAC for Neuroscience
SUMO-Fusion Protein Expression & Purification
Bacterial
SUMOpro E. Coli
SUMOstar
Advanced Therapeutic Applications
SUMOstar Mammalian
Ubiquitin E3 Ligase Assays, Drug Screening
Biochemical Assays
E3 Substrate Ubiquitination Assays
Gel-Based E3 Ligase Assay
Cell-Based E3 Substrate Assays
Novel E3 Ligases For PROTAC
Molecular Glue Degraders
In Vivo E3 Substrate Validation Assays
Thermal Shift Assay for E3 Ligases
Surface Plasmon Resonance for E3 Ligases
DUB Assays Screening & Profiling
Ubiquitin Flourophore Assays (Rhodamine, AMC, VME)
Ubiquitin Mass Spectrometry Proteomics
TUBE-Based Mass Spectrometry
E3 Ligase Substrate ID
DUB Substrate ID
Whole Cell Proteomics
Target Substrate ID
Ubiquitin Chain Diversity ID
Ligand Binding Assays
Thermal Shift Assays
Surface Plasmon Resonance
Fluorescence Polarization
Custom Solutions
Resources
Close Resources
Open Resources
Learning Center
Ubiquitin Proteasome System
Therapeutic Relevance
Applications
FAQs
Protacs
TUBEs
SUMO
Media
Close Media
Open Media
Press Releases
Unveiling the Power of Molecular Glues at the 6th Annual Targeted Protein Degradation Summit
LifeSensors Inc. Receives $5.53 Million Funds from National Institutes of Health to Develop PROTAC Drug Discovery and Diagnosis of Alzheimer’s Disease
LifeSensors is invited to speak at Discovery on Target 2023 – Breakthrough Molecules with Unique Molecular Glue & PROTAC Platform
All Releases
Scientific Posters
Accelerating PROTAC drug discovery: Establishing a relationship between ubiquitination and target protein degradation
Discovering Unique Ubiquitin E3 Ligase Ligands to Unlock Targeted Protein Degradation
PROTACs and Molecular Glues: High-Throughput Quantitative Assays for Rationale Design
View More
Publications & Blogs
Parkin Unveiled: Paving the Way for Breakthroughs in Neurodegenerative Research
Unveiling the Power of TUBEs: Revolutionizing Ubiquitin Research
Unveiling the Power of Molecular Glues at the 6th Annual Targeted Protein Degradation Summit
Read More Blogs
Search
$
0.00
0
Cart
Questions about a product, technology or experimental design? Give us a call 610-644-8845.
BLOG
Home
BLOG
Parkin Unveiled: Paving the Way for Breakthroughs in Neurodegenerative Research
Unveiling the Power of TUBEs: Revolutionizing Ubiquitin Research
LifeSensors Inc. Receives $5.53 Million Funds from National Institutes of Health to Develop PROTAC Drug Discovery and Diagnosis of Alzheimer’s Disease
Tragedy to Transformation – Molecular Glue Sparks the Field of Targeted Protein Degradation
Drug Discovery with UbiTest Technology
Accelerating PROTAC drug discovery: Establishing a relationship between ubiquitination and target protein degradation
Discovering Unique Ubiquitin E3 Ligase Ligands to Unlock Targeted Protein Degradation
PROTACs and Molecular Glues: High-Throughput Quantitative Assays for Rationale Design
Profiling E3 ligase compounds and the Implications in Drug Discovery
Accelerating PROTAC drug discovery: Establishing a Relationship Between Ubiquitination and Target Protein Degradation
PROTAC Drug Discovery January 2022 Webinar
The Power of PROTACs
Plunging into the Plight of Parkinson’s Disease
Ubiquitin-Proteasome System
The Biomarkers of Alzheimer’s Disease
SARS-CoV-2 Antigens
LifeSensor’s COVID-19 IgG Detection Kit Receives FDA Provisional Approval
LifeSensors Inc Launches ELISA Kits- IgG & IgG/IgM/IgA To Combat COVID19
LifeSensors, Inc COVID-19 Test Processing Laboratory
Novel Approaches to PROTAC® Drug Discovery
Load More
✕
